Chemotherapy of Leukemia in Mice, Rats, and Humans Relating Time of Humoral Stimulation, Tumor Growth, and Clinical Response23
- 1 September 1981
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 67 (3) , 529-538
- https://doi.org/10.1093/jnci/67.3.529
Abstract
Studies were conducted in the leukemic mouse and rat to test the hypothesis that enhanced effects of drugs given in sequence relate to a predictable increase in tumor growth and sensitivity to cycle-active agents. The rationale is based on a) evidence that, following drug-induced aplasia, resultant bone marrow proliferation in vivo corresponds temporally with induced humoral stimulatory activity, and on b) models that demonstrate increased cytotoxicity of β-cytosine arabinoside (Ara-C) to myeloblasts cultured in humoral stimulatory activity (HSA). CD2F1 mice bearing L-1210 leukemia received a course of 60 mg Ara-C/kg every 8th hour (q.8 h) three times on day 0 and on another day in sequence (0.1 through 0.7). The longest survival (250% of controls) was in animals whose second course began on day 3, the time of peak HSA as measured by DNA synthesis induced in L-1210 cells in culture. LBN rats bearing acute myelocytic leukemia (AML) were treated with 100 mg Ara-C/kg q.8 h six times begining on day 0 and on other days in sequence (0.1 through 0.12). The longest survival was in those treated on day 0.6 (760% of controls), the time of peak serum stimulation, and tumor labeling index (LI). Thirty-seven patients with AML received a single course of therapy with 45 mg Ara-C/kg by a 72-hour infusion and 1.0 mg daunorubicin/kg every day three times. On day 8, the time of peak HSA and tumor LI, Ara-C was again infused. Complete remission was achieved in 56% (65% of all patients <60 yr old) with a single cycle of therapy. Median duration of chemotherapy-free remission was 10 months. Of 11 relapsing patients, 8 achieved a second remission with the same regimen. These studies demonstrated that the amount of proliferation of residual tumor and thereby sensitivity to cycle-active drugs given in sequence relates to the initial drug effect on tumor proliferation and the induction of humoral stimulation.Keywords
This publication has 9 references indexed in Scilit:
- Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols.A clinical-pathologic study of 33 patientsCancer, 1978
- BN RAT MYELOID-LEUKEMIA TRANSFERRED TO (LEW X BN)F1 RAT1978
- INTERMITTENT HIGH-DOSE CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF LUNG1978
- Cellular Quantitation of In Vivo Effects of 1-β-d-Arabinofuranosylcytosine on Leukemia L12102JNCI Journal of the National Cancer Institute, 1977
- TIMED SEQUENTIAL THERAPY OF HUMAN LEUKEMIA BASED UPON RESPONSE OF LEUKEMIC-CELLS TO HUMORAL GROWTH-FACTORS1977
- INDUCTION OF SERUM STIMULATION AND PLASMA-CELL PROLIFERATION DURING CHEMOTHERAPY OF MULTIPLE-MYELOMA1977
- ENHANCEMENT OF DRUG CYTOTOXICITY BY RECRUITMENT OF LEUKEMIC MYELOBLASTS WITH HUMORAL STIMULATION1976
- SEPARATE AND SEQUENTIAL CHEMOTHERAPY OF MOUSE LEUKEMIA L1210 WITH 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE AND 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA1967
- CHEMOTHERAPY OF LEUKEMIA L1210 IN MICE WITH 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE .I. INFLUENCE OF TREATMENT SCHEDULES1966